GlassScriptPhysician profile
Jill Farrell
NPI 1710415088
$2,056.94
in general payments reported to CMS, 2019-2025
26 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2023: $978 · 2024: $691 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.57 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $271.57 | 2023-2025 | |
| Novo Nordisk INC | $262.92 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $174.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $151.80 | 2023-2024 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $120.06 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $112.35 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $86.97 | 2023 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $71.94 | 2023-2024 | Xarelto |
| Lundbeck LLC | $70.90 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $61.51 | 2023-2024 | Dificid, Steglatro, Belsomra |
| Avanir Pharmaceuticals, INC. | $47.58 | 2022 | |
| Dynavax Technologies Corporation | $41.52 | 2024 | Heplisav-B |
| Procept Biorobotics Corporation | $34.74 | 2024 | Aquabeam System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.73 | 2025 | Ofev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.18 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.59 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $22.15 | 2022 | |
| Inspire Medical Systems, INC. | $20.30 | 2024 | Inspire |
| Grifols USA, LLC | $19.29 | 2025 | Prolastin-C Liquid |
| Avvisto Therapeutics, LLC | $18.42 | 2024 | Cycloset |
| Glaxosmithkline, LLC. | $18.18 | 2022 | |
| Dexcom, INC. | $18.03 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $14.65 | 2024 | (Ck7) Extended Holter |
| Amarin Pharma, INC. | $13.76 | 2023 | |
| Ardelyx, INC. | $13.60 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.